Six Months of Data Show 91.3% Efficacy for Pfizer Vaccine in Adults
Updated Phase 3 data analyzing the Pfizer-BioNTech COVID-19 vaccine up to six months after second vaccination showed it was 91.3% effective overall and 100% effective versus severe disease.